FDA Grants Accelerated Approval to Pirtobrutinib For Relapsed or Refractory Mantle Cell Lymphoma
On January 27, 2023, the Food and Drug Administration (FDA) granted accelerated approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. Read more.